Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Q4 2021 Oncopeptides AB Earnings Call Transcript

Feb 17, 2022 / 02:00PM GMT
Release Date Price: kr6.56 (-1.31%)
Operator

Welcome to the Oncopeptides Audiocast with Teleconference Q4 2021. (Operator Instructions) Today, I am pleased to present CEO, Jakob Lindberg, CFO; Annika Muskantor and CMO, Klaas Bakker. Please go ahead with your meeting.

Jakob Lindberg;publ;CEO
Oncopeptides AB

()-

Thank you, Jakob Lindberg here. Good afternoon. Good morning to those on the other side of the Atlantic. We are here today to report our Q4 report and the webcast associated with that. As you know, we have had some significantly positive events lately. Unfortunately, just like on our last webcast, we cannot go into details regarding the scientific rationale for our actions. We will, of course, at some point in time, share them with you when we can, but we can't at this point in time. But we will highlight how we judge them and hence, help you make your assessment of it.

Please go to Slide #2. As you know that this webcast is regulated, and you should make your own assessment of the data that we provide. And for any type of information and our forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot